Drug Research
King Pharmaceuticals and Acura Pharmaceuticals Announce Submission of New Drug Application for ACUROX Tablets
King Pharmaceuticals®, Inc. and Acura Pharmaceuticals, Inc. announced that King has submitted a New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets to the U.S. Food and Drug Administration (FDA), including a request for priority review classification. ACUROX® is...
Drug Research
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib
Pfizer Inc. announced that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26...
Articles
Bottlenecks in vaccine development: Eliminate from the beginning
Promising vaccine candidates, rising global demand and preparations for the next pandemic influenza have brought vaccine’s role into focus in the past years and resulted in an impressive Pharma market share and revenue (US$ 26billion) in 2009. This...
Drug Research
New technique to speed up drug development
Scientists working at the European Molecular Biology Laboratory in Grenoble, France have developed a new technique that enables them to introduce up to 15 fluorescent markers to a mammalian cell in one go. They say their findings could help...
Drug Research
Optimer Pharmaceuticals Completes New Drug Application for Fidaxomicin
Optimer Pharmaceuticals, Inc.announced that it has completed the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI....
Drug Research
New data show potential for Novartis Meningitis B vaccine
New data demonstrated that antibodies induced by Novartis Vaccines investigational, four component, Meningococcal Serogroup B Vaccine (4CMenB) killed the majority of a collection of geographically and genetically diverse meningococcal serogroup B (MenB) strains. The strain coverage research findings were...
Drug Research
Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
Amgen announced that it has won the Best New Drug awardfor Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the2010 Scrip Awards...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read